2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...
Vidac Pharma Holding plc reports preclinical proof of principle
Vidac Pharma Holdings plc will report promising results for its cancer drug candidate VDA-1275 in multiple mouse cancer and human cellular...
Novartis AG to buy immunology specialist Calypso Biotech BV
Upon closure, the US$425m take-over of the Amsterdam-headquartered Calypso Biotech NV, would give Novartis AG full commercialisation rights to...
£26m for Cystic Fibrosis Drug Trial
With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m (~€30.5m) for the Phase...
Roche leads Freenome Inc US$257m financing
Roche led the financing that will be used by San Francisco-based Freenome Inc to finance testing its early cancer detection platform in the Vallania...
GLP1 agonists: FDA investigates suicide risk
It is rare for the US Food and Drug Administration (FDA) to act more slowly than its European counterpart, the EMA. However, this is the case with...